project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LM; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.59; rna integrity number: 8.8; age at index: 72; days to birth: -26377; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1941; age at diagnosis: 26377; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic n: N1; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 378.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 251; initial weight: 170.0; sample id: bfbe6bf9-86c3-41db-9081-8832e8cbc059; sample submitter id: TCGA-ZG-A9LM-01A; portion id: 7ed73257-1fa6-4db5-8743-65e9c00c3a32; portion submitter id: TCGA-ZG-A9LM-01A-11; slide id: b81d5dd3-9c4c-4a14-84f6-4056a64a0f89; slide submitter id: TCGA-ZG-A9LM-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;